EDG-5506

Edgewise Therapeutics is prioritizing the completion of recruitment for the GRAND CANYON trial for Becker muscular dystrophy in early 2025.

The FDA has placed a clinical hold on PepGen's Phase 2 CONNECT2-EDO51 trial for PGN-EDO51 in Duchenne muscular dystrophy (DMD) due to regulatory questions.

Edgewise Therapeutics' sevasemten met the primary endpoint in its Phase 2 CANYON trial, significantly reducing creatine kinase levels in Becker muscular dystrophy patients.

Edgewise Therapeutics is advancing EDG-7500 for HCM, with a readout expected in September, showing potential to reduce titration needs.

Wave Life Sciences reported positive interim results for WVE-N531, an exon-skipping oligonucleotide, showing promising dystrophin expression in patients with Duchenne muscular dystrophy.